国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

美國Atossa Genetics
我們的第一個產(chǎn)品和服務是乳腺細胞吸取器檢測(MASCTSystem?). 這個已經(jīng)美國國家食品衛(wèi)生檢驗局許可的取樣及細胞測試系統(tǒng)只需10 分鐘的取樣，且是無痛的。此項檢測可提早幾年偵測癌變細胞。

我們透過研究及開發(fā)，推出的創(chuàng)新產(chǎn)品和服務來協(xié)助醫(yī)護人員維持女性健康和福利。進而預防、診斷及治療包括癌癥有關乳房的疾病。

我們是一家醫(yī)療保健公司專注于開發(fā)和銷售為乳腺癌風險評估的新型細胞和分子診斷產(chǎn)品。

We are a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer.

Using our patented, FDA-approved Mammary Aspirate Specimen Cytology Test (MASCT) System, a nurse or physician’s assistant, can painlessly collect a sample of Nipple Aspirate Fluid (NAF) in about 10 minutes. The NAF sample contains cells (cytology) and molecular diagnostic biomarkers that are useful in finding cancers and pre-cancerous changes, especially Atypical Ductal Hyperplasia (ADH), which confers a higher risk of developing breast cancer.

The FDA has determined, based on clinical trial data, that the MASCT System can be used in the determination and/or differentiation of normal versus premalignant versus malignant cells. Cytology changes in NAF have been shown to occur up to eight years before changes can be picked up by mammography.

Our name comes from Atossa, daughter of Cyrus the Great and wife of Darius I, the King of the Achaemenid Empire. In about 470 BC she became the first woman in recorded history to be diagnosed with breast cancer.